Yuichi Nomura1,2, Yoshitaka Asano3,4, Jun Shinoda3,4, Hirohito Yano5, Yuka Ikegame3,4, Tomohiro Kawasaki3,5, Noriyuki Nakayama5, Takashi Maruyama6, Yoshihiro Muragaki6, Toru Iwama5. 1. Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, 630 Shimo-kobi, Kobi-cho, Minokamo, Gifu, 505-0034, Japan. roka970201@yahoo.co.jp. 2. Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan. roka970201@yahoo.co.jp. 3. Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, 630 Shimo-kobi, Kobi-cho, Minokamo, Gifu, 505-0034, Japan. 4. Department of Clinical Brain Sciences, Gifu University Graduate School of Medicine, Minokamo, Japan. 5. Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan. 6. Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Abstract
PURPOSE: The aim of this study was to assess whether dynamic PET with 11C-methionine (MET) (MET-PET) is useful in the diagnosis of brain tumors. METHODS: One hundred sixty patients with brain tumors (139 gliomas, 9 meningiomas, 4 hemangioblastomas and 8 primary central nervous system lymphomas [PCNSL]) underwent dynamic MET-PET with a 3-dimensional acquisition mode, and the maximum tumor MET-standardized uptake value (MET-SUV) was measured consecutively to construct a time-activity curve (TAC). Furthermore, receiver operating characteristic (ROC) curves were generated from the time-to-peak (TTP) and the slope of the curve in the late phase (SLOPE). RESULTS: The TAC patterns of MET-SUVs (MET-TACs) could be divided into four characteristic types when MET dynamics were analyzed by dividing the MET-TAC into three phases. MET-SUVs were significantly higher in early and late phases in glioblastoma compared to anaplastic astrocytoma, diffuse astrocytoma and the normal frontal cortex (P < 0.05). The SLOPE in the late phase was significantly lower in tumors that included an oligodendroglial component compared to astrocytic tumors (P < 0.001). When we set the cutoff of the SLOPE in the late phase to - 0.04 h-1 for the differentiation of tumors that included an oligodendroglial component from astrocytic tumors, the diagnostic accuracy was 74.2% sensitivity and 64.9% specificity. The area under the ROC curve was 0.731. CONCLUSIONS: The results of this study show that quantification of the MET-TAC for each brain tumor identified by a dynamic MET-PET study could be helpful in the non-invasive discrimination of brain tumor subtypes, in particular gliomas.
PURPOSE: The aim of this study was to assess whether dynamic PET with 11C-methionine (MET) (MET-PET) is useful in the diagnosis of brain tumors. METHODS: One hundred sixty patients with brain tumors (139 gliomas, 9 meningiomas, 4 hemangioblastomas and 8 primary central nervous system lymphomas [PCNSL]) underwent dynamic MET-PET with a 3-dimensional acquisition mode, and the maximum tumor MET-standardized uptake value (MET-SUV) was measured consecutively to construct a time-activity curve (TAC). Furthermore, receiver operating characteristic (ROC) curves were generated from the time-to-peak (TTP) and the slope of the curve in the late phase (SLOPE). RESULTS: The TAC patterns of MET-SUVs (MET-TACs) could be divided into four characteristic types when MET dynamics were analyzed by dividing the MET-TAC into three phases. MET-SUVs were significantly higher in early and late phases in glioblastoma compared to anaplastic astrocytoma, diffuse astrocytoma and the normal frontal cortex (P < 0.05). The SLOPE in the late phase was significantly lower in tumors that included an oligodendroglial component compared to astrocytic tumors (P < 0.001). When we set the cutoff of the SLOPE in the late phase to - 0.04 h-1 for the differentiation of tumors that included an oligodendroglial component from astrocytic tumors, the diagnostic accuracy was 74.2% sensitivity and 64.9% specificity. The area under the ROC curve was 0.731. CONCLUSIONS: The results of this study show that quantification of the MET-TAC for each brain tumor identified by a dynamic MET-PET study could be helpful in the non-invasive discrimination of brain tumor subtypes, in particular gliomas.
Authors: Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2012-12-12 Impact factor: 9.236
Authors: Niklas Thon; Mathias Kunz; Lena Lemke; Nathalie L Jansen; Sabina Eigenbrod; Simone Kreth; Jürgen Lutz; Rupert Egensperger; Armin Giese; Jochen Herms; Michael Weller; Hans Kretzschmar; Jörg-Christian Tonn; Christian la Fougère; Friedrich-Wilhelm Kreth Journal: Int J Cancer Date: 2014-11-03 Impact factor: 7.396
Authors: T Kato; J Shinoda; N Oka; K Miwa; N Nakayama; H Yano; T Maruyama; Y Muragaki; T Iwama Journal: AJNR Am J Neuroradiol Date: 2008-08-07 Impact factor: 3.825